dapsone has been researched along with Anemia, Hemolytic, Acquired in 82 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "After treatment with dapsone gel, 5%, no clinical or laboratory evidence of drug-induced hemolytic anemia was noted in G6PD-deficient subjects with acne vulgaris." | 9.13 | Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008) |
| "Literature retrieval was accessed through MEDLINE (1966-March 2011), Cochrane Library, and EMBASE, using the terms dapsone and methemoglobinemia." | 8.87 | Dapsone-induced methemoglobinemia: a primer for clinicians. ( Barclay, JA; Ibrahim, RB; Ziemba, SE, 2011) |
| " CASE REPORT A 22-year-old woman, who was diagnosed with multibacillary leprosy, developed dapsone-induced methemoglobinemia and hemolytic anemia, complicated by melioidosis." | 8.02 | Challenges in Managing a Lepromatous Leprosy Patient Complicated with Melioidosis Infection, Dapsone-Induced Methemoglobinemia, Hemolytic Anemia, and Lepra Reaction. ( Chew, LP; Chua, HH; Fam, TL; Lee, JTH; Muniandy, P; Tang, ASO; Ting, IPL; Wong, QY; Yeo, ST, 2021) |
| "Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin." | 7.78 | Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. ( Deps, P; Guerra, P; Nasser, S; Simon, M, 2012) |
| "Dapsone hypersensitivity syndrome (DHS) is a potentially life-threatening adverse drug reaction consisting of fever, hepatitis, exfoliative dermatitis, lymphadenopathy and hemolytic anemia." | 7.75 | Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. ( Chu, CY; Sheen, YS; Tsai, TF; Wang, SH, 2009) |
| "The treatment of two common adverse effects of dapsone (methemoglobinemia and hemolytic anemia) is discussed, and a case of acute dapsone intoxication is described." | 7.68 | Dapsone-induced methemoglobinemia and hemolytic anemia. ( Erstad, BL, 1992) |
| "A case of dapsone-induced severe haemolytic anaemia and agranulocytosis is described." | 7.67 | Dapsone-induced haemolytic anaemia and agranulocytosis in a patient with normal glucose-6-phosphate-dehydrogenase activity. ( Figueiredo, MS; Pinto, BO; Zago, MA, 1989) |
| "The authors report 8 cases of Horton's disease and/or polymyalgia rheumatica treated with prednisone with an initially favourable result." | 7.67 | [Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica]. ( Celton, H; Doury, P; Eulry, F; Fabresse, FX; Larroque, P; Pattin, S, 1984) |
| "Fifty one patients with leprosy from the Urban Leprosy Centre, attached to the Department of Dermatology and Venereology, Goa Medical College on treatment with Dapsone were studied from the point of view of development of haemolysis related to the drug." | 7.66 | Dapsone haemolysis in leprosy. A preliminary report. ( Menezes, S; Rege, VL; Sehgal, VN, 1981) |
| "Twenty patients with dermatitis herpetiformis treated with di(4-aminophenyl)-sulphone (Dapsone) were analyzed with respect to serum hemopexin concentration as well as some other haematological parameters." | 7.65 | Serum hemopexin in patients with dermatitis herpetiformis on dapsone (di(4-aminophenyl)sulphone). ( Kastrup, W; Lindstedt, G; Lundberg, PA; Mobacken, H, 1975) |
| "Malaria is a leading cause of mortality, particularly in sub-Saharan African children." | 6.77 | Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria. ( Bassat, Q; D' Alessandro, U; Daniel, A; Forret, P; González, R; Machevo, S; Nabasumba, C; Piola, P; Robert, A; Talisuna, A; Turyakira, E; Van Geertruyden, JP; van Loen, H; Van Malderen, C; Van Overmeir, C; Yeka, A, 2012) |
| " There are several potential mechanisms by which histone deacetylase inhibition may alter dapsone metabolism including changes in hepatic acetylation or N-glucuronidation leading to an increase in the bioavailability of dapsone's hematotoxic metabolites." | 5.42 | Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone. ( Harmon, M; Lesser, GJ; Lewis, JA; Owen, J; Peacock, JE; Petty, WJ; Pirmohamed, M; Valente, K, 2015) |
| "We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone." | 5.38 | Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. ( Blanton, LS; East, J, 2012) |
| "Dapsone therapy was initiated on day +28 at a dose of 100 mg/day for PCP prophylaxis secondary to the patient's history of a sulfonamide allergy." | 5.33 | The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. ( Abidi, MH; Ibrahim, RB; Kozlowski, JR; Peres, E, 2006) |
| "Jaundice was due to cholestasis in two cases and to hemolysis in the third." | 5.26 | Dapsone-induced jaundice. ( Goodwin, RM; Stone, SP, 1978) |
| "After treatment with dapsone gel, 5%, no clinical or laboratory evidence of drug-induced hemolytic anemia was noted in G6PD-deficient subjects with acne vulgaris." | 5.13 | Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris. ( Jarratt, M; Pariser, D; Piette, WW; Sheth, P; Taylor, S; Wilson, D, 2008) |
| "Literature retrieval was accessed through MEDLINE (1966-March 2011), Cochrane Library, and EMBASE, using the terms dapsone and methemoglobinemia." | 4.87 | Dapsone-induced methemoglobinemia: a primer for clinicians. ( Barclay, JA; Ibrahim, RB; Ziemba, SE, 2011) |
| " CASE REPORT A 22-year-old woman, who was diagnosed with multibacillary leprosy, developed dapsone-induced methemoglobinemia and hemolytic anemia, complicated by melioidosis." | 4.02 | Challenges in Managing a Lepromatous Leprosy Patient Complicated with Melioidosis Infection, Dapsone-Induced Methemoglobinemia, Hemolytic Anemia, and Lepra Reaction. ( Chew, LP; Chua, HH; Fam, TL; Lee, JTH; Muniandy, P; Tang, ASO; Ting, IPL; Wong, QY; Yeo, ST, 2021) |
| "Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin." | 3.78 | Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy. ( Deps, P; Guerra, P; Nasser, S; Simon, M, 2012) |
| "Dapsone hypersensitivity syndrome (DHS) is a potentially life-threatening adverse drug reaction consisting of fever, hepatitis, exfoliative dermatitis, lymphadenopathy and hemolytic anemia." | 3.75 | Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan. ( Chu, CY; Sheen, YS; Tsai, TF; Wang, SH, 2009) |
| "Multidrug therapy (WHO/MDT) in multibacillary leprosy consists of treatment with rifampicin, dapsone and clofazimine." | 3.75 | Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report. ( Guedes Filho, G; Guedes, WR; Oliveira, BB; Oliveira, CA; Oliveira, DA; Silva, IM, 2009) |
| "Dapsone, used for prevention of Pneumocystis jirovecii infections, has been reported to cause hemolytic anemia and methemoglobinemia; its tolerability in solid organ transplant recipients is not well described." | 3.73 | Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. ( Barton, TD; Bloom, RD; Blumberg, EA; Chojnowski, D; Doyle, AM; Goral, S; Korenda, K; Lee, I, 2005) |
| "The treatment of two common adverse effects of dapsone (methemoglobinemia and hemolytic anemia) is discussed, and a case of acute dapsone intoxication is described." | 3.68 | Dapsone-induced methemoglobinemia and hemolytic anemia. ( Erstad, BL, 1992) |
| "A 65-year-old man on maintenance dapsone therapy for dermatitis herpetiformis for 30 years was admitted to hospital with acute abdominal pain and vomiting." | 3.68 | Gall-bladder perforation after long-term dapsone therapy. ( Choy, AM; Lang, CC, 1990) |
| "The authors report 8 cases of Horton's disease and/or polymyalgia rheumatica treated with prednisone with an initially favourable result." | 3.67 | [Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica]. ( Celton, H; Doury, P; Eulry, F; Fabresse, FX; Larroque, P; Pattin, S, 1984) |
| "A case of dapsone-induced severe haemolytic anaemia and agranulocytosis is described." | 3.67 | Dapsone-induced haemolytic anaemia and agranulocytosis in a patient with normal glucose-6-phosphate-dehydrogenase activity. ( Figueiredo, MS; Pinto, BO; Zago, MA, 1989) |
| "Fifty one patients with leprosy from the Urban Leprosy Centre, attached to the Department of Dermatology and Venereology, Goa Medical College on treatment with Dapsone were studied from the point of view of development of haemolysis related to the drug." | 3.66 | Dapsone haemolysis in leprosy. A preliminary report. ( Menezes, S; Rege, VL; Sehgal, VN, 1981) |
| "5 g of 4,4'-diamino, diphenyl sulphone (dapsone) taken as a suicide attempt in a patient on long-term therapy for tuberculoid leprosy resulted in permanent bilateral retinal necrosis, previously unreported side effect of this drug." | 3.66 | Permanent retinal damage following massive dapsone overdose. ( Agnello, R; Chester, GH; Holt, K; Kenner, DJ, 1980) |
| "Twenty patients with dermatitis herpetiformis treated with di(4-aminophenyl)-sulphone (Dapsone) were analyzed with respect to serum hemopexin concentration as well as some other haematological parameters." | 3.65 | Serum hemopexin in patients with dermatitis herpetiformis on dapsone (di(4-aminophenyl)sulphone). ( Kastrup, W; Lindstedt, G; Lundberg, PA; Mobacken, H, 1975) |
| "Malaria is a leading cause of mortality, particularly in sub-Saharan African children." | 2.77 | Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria. ( Bassat, Q; D' Alessandro, U; Daniel, A; Forret, P; González, R; Machevo, S; Nabasumba, C; Piola, P; Robert, A; Talisuna, A; Turyakira, E; Van Geertruyden, JP; van Loen, H; Van Malderen, C; Van Overmeir, C; Yeka, A, 2012) |
| "Dapsone may be used for Pneumocystis jirovecii pneumonia (PJP) prophylaxis in hematology patients receiving immunosuppressive therapy or after hematopoietic stem cell transplant (HSCT) in the setting of trimethoprim-sulfamethoxazole (TMP-SMX) adverse drug reaction (ADR) history." | 1.48 | Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients. ( Pisasale, D; Trubiano, JA; Urbancic, KF; Wight, J, 2018) |
| "Hemolytic anemia is one of the complications related to the chronic consumption of dapsone." | 1.43 | Incidence and patterns of hemolytic anemia in acute dapsone overdose. ( Cha, K; Cha, YS; Hwang, SO; Kim, H; Kim, HI; Kim, J; Kim, OH; Lee, KH, 2016) |
| " There are several potential mechanisms by which histone deacetylase inhibition may alter dapsone metabolism including changes in hepatic acetylation or N-glucuronidation leading to an increase in the bioavailability of dapsone's hematotoxic metabolites." | 1.42 | Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone. ( Harmon, M; Lesser, GJ; Lewis, JA; Owen, J; Peacock, JE; Petty, WJ; Pirmohamed, M; Valente, K, 2015) |
| " Drug-induced acute hemolytic anemia in G6PD A- subjects can be life-threatening, depending on the nature and dosage of the drug trigger." | 1.38 | Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. ( Carter, N; Duparc, S; Luzzatto, L; Pamba, A; Premji, Z; Richardson, ND; Tiono, AB, 2012) |
| "We report two cases of symptomatic hyperbilirubinemia attributed to atazanavir in conjunction with the Pneumocystis jirovecii pneumonia prophylaxis agent dapsone." | 1.38 | Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy. ( Blanton, LS; East, J, 2012) |
| "Overall, 75 (6." | 1.36 | Prevalence of G6PD deficiency in a large cohort of HIV-infected patients. ( Giordano, TP; Serpa, JA; Villarreal-Williams, E, 2010) |
| " Although current CDC guidelines do not recommend adjusting dose by IBW or renal function, we suggest that consideration should be given to these dosing strategies." | 1.35 | Dapsone-induced hemolytic anemia in lung allograft recipients. ( Force, S; Lawrence, EC; Lyon, GM; Naik, PM; Neujahr, DC; Pelaez, A; Ramirez, A, 2008) |
| "Dapsone therapy was initiated on day +28 at a dose of 100 mg/day for PCP prophylaxis secondary to the patient's history of a sulfonamide allergy." | 1.33 | The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation. ( Abidi, MH; Ibrahim, RB; Kozlowski, JR; Peres, E, 2006) |
| "Dapsone hydroxylamine is a direct-acting hemolytic agent responsible for dapsone-induced hemolytic anemia in the rat." | 1.29 | Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulfhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes. ( Budinsky, RA; Jollow, DJ; McMillan, DC; Simson, JV, 1995) |
| "Epiandrosterone was found to inhibit rat red cell G6PD uncompetitively and to suppress red cell hexose monophosphate shunt activity by more than 95%." | 1.29 | Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone. ( Budinsky, R; Grossman, S; Jollow, D, 1995) |
| "A young female presented with haemolytic anaemia due to dapsone overdosage." | 1.28 | Peripheral neuropathy and haemolytic anaemia with cherry red spot on macula in dapsone poisoning. ( Abhayambika, K; Chacko, A; Mahadevan, K; Najeeb, OM, 1990) |
| "Dapsone has been used since 1976 in the treatment of relapsing polychondritis." | 1.27 | [Chronic atrophic polychondritis. Critical analysis of the therapeutic efficacy of dapsone. 2 cases]. ( Abadie, JC; Gouet, D; Marechaud, R; Neau, JP; Rossi, F; Sudre, Y, 1984) |
| "It was concluded that haemolytic anaemia after dapsone therapy is not due to a functional impairment of the enzyme." | 1.26 | Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage. ( Allegra, F; De Panfilis, G; Manfredi, G; Zampetti, M, 1979) |
| "A description of the clinical and biochemical course is given for a patient who developed haemolysis and methaemoglobinaemia following dapsone therapy in high dosage for 2 weeks." | 1.26 | High dose dapsone toxicity. ( Goldwein, MI; Shelley, WB, 1976) |
| "Jaundice was due to cholestasis in two cases and to hemolysis in the third." | 1.26 | Dapsone-induced jaundice. ( Goodwin, RM; Stone, SP, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 37 (45.12) | 18.7374 |
| 1990's | 10 (12.20) | 18.2507 |
| 2000's | 14 (17.07) | 29.6817 |
| 2010's | 15 (18.29) | 24.3611 |
| 2020's | 6 (7.32) | 2.80 |
| Authors | Studies |
|---|---|
| Vandermeersch, D | 1 |
| Sansen, PY | 1 |
| Pothen, L | 1 |
| Toyoshima, T | 1 |
| Harada, Y | 1 |
| Morikawa, T | 1 |
| Shimizu, T | 1 |
| Rogers, LR | 1 |
| Oppelt, P | 1 |
| Nayak, L | 1 |
| Bartakke, SP | 1 |
| Sampagar, AA | 1 |
| Reddy, NA | 1 |
| Kangle, R | 1 |
| Rassner, M | 1 |
| Jung, J | 1 |
| Schneider, J | 1 |
| Wäsch, R | 1 |
| Engelhardt, M | 1 |
| Tang, ASO | 1 |
| Wong, QY | 1 |
| Yeo, ST | 1 |
| Ting, IPL | 1 |
| Lee, JTH | 1 |
| Fam, TL | 1 |
| Chew, LP | 1 |
| Chua, HH | 1 |
| Muniandy, P | 1 |
| Urbancic, KF | 1 |
| Pisasale, D | 1 |
| Wight, J | 1 |
| Trubiano, JA | 1 |
| Rochford, R | 1 |
| Ohrt, C | 1 |
| Baresel, PC | 1 |
| Campo, B | 1 |
| Sampath, A | 1 |
| Magill, AJ | 1 |
| Tekwani, BL | 1 |
| Walker, LA | 1 |
| Luzzatto, L | 3 |
| Seneca, E | 1 |
| Lewis, JA | 1 |
| Petty, WJ | 1 |
| Harmon, M | 1 |
| Peacock, JE | 1 |
| Valente, K | 1 |
| Owen, J | 1 |
| Pirmohamed, M | 1 |
| Lesser, GJ | 1 |
| Cha, YS | 1 |
| Kim, H | 1 |
| Kim, J | 1 |
| Kim, OH | 1 |
| Kim, HI | 1 |
| Cha, K | 1 |
| Lee, KH | 1 |
| Hwang, SO | 1 |
| Flosadóttir, E | 1 |
| Bjarnason, B | 1 |
| Naik, PM | 1 |
| Lyon, GM | 1 |
| Ramirez, A | 1 |
| Lawrence, EC | 1 |
| Neujahr, DC | 1 |
| Force, S | 1 |
| Pelaez, A | 1 |
| Mobacken, H | 2 |
| Piette, WW | 1 |
| Taylor, S | 1 |
| Pariser, D | 1 |
| Jarratt, M | 1 |
| Sheth, P | 1 |
| Wilson, D | 1 |
| Ranawaka, RR | 1 |
| Mendis, S | 1 |
| Weerakoon, HS | 1 |
| Sheen, YS | 1 |
| Chu, CY | 1 |
| Wang, SH | 1 |
| Tsai, TF | 1 |
| Goolamali, SI | 1 |
| Macfarlane, CS | 1 |
| Silva, IM | 1 |
| Oliveira, CA | 1 |
| Guedes, WR | 1 |
| Oliveira, BB | 1 |
| Oliveira, DA | 1 |
| Guedes Filho, G | 1 |
| Serpa, JA | 1 |
| Villarreal-Williams, E | 1 |
| Giordano, TP | 1 |
| Barclay, JA | 1 |
| Ziemba, SE | 1 |
| Ibrahim, RB | 2 |
| East, J | 1 |
| Blanton, LS | 1 |
| Van Malderen, C | 1 |
| Van Geertruyden, JP | 1 |
| Machevo, S | 1 |
| González, R | 1 |
| Bassat, Q | 1 |
| Talisuna, A | 1 |
| Yeka, A | 1 |
| Nabasumba, C | 1 |
| Piola, P | 1 |
| Daniel, A | 1 |
| Turyakira, E | 1 |
| Forret, P | 1 |
| Van Overmeir, C | 1 |
| van Loen, H | 1 |
| Robert, A | 1 |
| D' Alessandro, U | 1 |
| Durant, C | 1 |
| Hadj-Khelifa, S | 1 |
| Lei, J | 1 |
| Badaoui, A | 1 |
| Moreau, AS | 1 |
| Traineau, R | 1 |
| Farge, D | 1 |
| Decaux, O | 1 |
| Pamba, A | 1 |
| Richardson, ND | 1 |
| Carter, N | 1 |
| Duparc, S | 1 |
| Premji, Z | 1 |
| Tiono, AB | 1 |
| Desenfants, A | 1 |
| Huguon, E | 1 |
| Polfrit, Y | 1 |
| Crouzat, M | 1 |
| Rouleau, V | 1 |
| Chassot, V | 1 |
| Besson-Leaud, L | 1 |
| Missotte, I | 1 |
| Lozinski, A | 1 |
| Baum, S | 1 |
| Sagi, L | 1 |
| Volkov, A | 1 |
| Trau, H | 1 |
| Barzilai, A | 1 |
| Deps, P | 1 |
| Guerra, P | 1 |
| Nasser, S | 1 |
| Simon, M | 1 |
| Abad Manteca, L | 1 |
| Justo Muradas, I | 1 |
| Pérez Castrillón, JL | 1 |
| Aviña-Zubieta, JA | 1 |
| Galindo-Rodrìguez, G | 1 |
| Robledo, I | 1 |
| Vela-Ojeda, J | 1 |
| Vadillo-Buenfil, M | 1 |
| Rosas-Cabral, A | 1 |
| Salazar-Exaire, D | 1 |
| SMITH, RS | 1 |
| ALEXANDER, S | 1 |
| DESFORGES, JF | 1 |
| THAYER, WW | 1 |
| DAWSON, JP | 1 |
| GISSLEN, H | 1 |
| HERSLE, K | 1 |
| RAMANUJAM, K | 1 |
| SMITH, M | 1 |
| Blackall, DP | 1 |
| Lee, I | 1 |
| Barton, TD | 1 |
| Goral, S | 1 |
| Doyle, AM | 1 |
| Bloom, RD | 1 |
| Chojnowski, D | 1 |
| Korenda, K | 1 |
| Blumberg, EA | 1 |
| Wertheim, MS | 1 |
| Males, JJ | 1 |
| Cook, SD | 1 |
| Tole, DM | 1 |
| Abidi, MH | 1 |
| Kozlowski, JR | 1 |
| Peres, E | 1 |
| Gouet, D | 1 |
| Marechaud, R | 1 |
| Neau, JP | 1 |
| Abadie, JC | 1 |
| Rossi, F | 1 |
| Sudre, Y | 1 |
| Tomecki, KJ | 1 |
| Catalano, CJ | 1 |
| Doury, P | 1 |
| Fabresse, FX | 1 |
| Pattin, S | 1 |
| Eulry, F | 1 |
| Celton, H | 1 |
| Larroque, P | 1 |
| Sanders, SW | 1 |
| Zone, JJ | 1 |
| Foltz, RL | 1 |
| Tolman, KG | 1 |
| Rollins, DE | 1 |
| De Prost, Y | 1 |
| Hornac, P | 1 |
| Galacteros, F | 1 |
| Penev, M | 1 |
| Revuz, J | 1 |
| Touraine, R | 1 |
| Pettit, JH | 2 |
| Menezes, S | 1 |
| Rege, VL | 1 |
| Sehgal, VN | 1 |
| Kenner, DJ | 1 |
| Holt, K | 1 |
| Agnello, R | 1 |
| Chester, GH | 1 |
| McMillan, DC | 3 |
| Simson, JV | 1 |
| Budinsky, RA | 1 |
| Jollow, DJ | 5 |
| Bradshaw, TP | 1 |
| Grossman, S | 1 |
| Budinsky, R | 1 |
| Jollow, D | 1 |
| Todd, P | 1 |
| Samaratunga, IR | 1 |
| Pembroke, A | 1 |
| Sin, DD | 1 |
| Shafran, SD | 1 |
| Jensen, CB | 1 |
| Manfredi, G | 1 |
| De Panfilis, G | 1 |
| Zampetti, M | 1 |
| Allegra, F | 1 |
| Stone, SP | 1 |
| Goodwin, RM | 1 |
| Shelley, WB | 1 |
| Goldwein, MI | 1 |
| Leiker, DL | 1 |
| Graham, WR | 1 |
| Cooney, T | 1 |
| Buckley, D | 1 |
| Doyle, C | 1 |
| Whelton, MJ | 1 |
| Fottrell, PF | 1 |
| Kastrup, W | 1 |
| Lindstedt, G | 1 |
| Lundberg, PA | 1 |
| Grossman, SJ | 2 |
| Simson, J | 1 |
| Erstad, BL | 1 |
| Abhayambika, K | 1 |
| Chacko, A | 1 |
| Mahadevan, K | 1 |
| Najeeb, OM | 1 |
| Choy, AM | 1 |
| Lang, CC | 1 |
| Figueiredo, MS | 1 |
| Pinto, BO | 1 |
| Zago, MA | 1 |
| Haas, M | 1 |
| Harrison, JH | 1 |
| Ismail, R | 1 |
| Wille, RC | 1 |
| Morrow, JD | 1 |
| Lachant, NA | 1 |
| Tanaka, KR | 1 |
| Brown, GV | 1 |
| Goldstein, BD | 1 |
| Hedstrand, H | 1 |
| Dugois, P | 1 |
| Amblard, P | 1 |
| Léger, J | 1 |
| Pinguet, JP | 1 |
| Khaire, DS | 1 |
| Magar, NG | 1 |
| Onadeko, BO | 1 |
| Bademosi, O | 1 |
| Hocking, DR | 1 |
| Sheehy, TW | 1 |
| Reba, RC | 1 |
| Neff, TA | 1 |
| Gaintner, JR | 1 |
| Tigertt, WD | 1 |
| Cream, JJ | 1 |
| Scott, GL | 1 |
| Schvartsman, S | 1 |
| Borges, MA | 1 |
| Mello, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ACZ ACN 01. A Phase 4, Double-Blind, Multicenter, Randomized, Vehicle-Controlled, Cross-Over Study to Further Evaluate the Risk of Hematological Adverse Events in G6PD-Deficient Subjects With Acne Vulgaris Treated With ACZONE™ (Dapsone) Gel, 5%.[NCT00243542] | Phase 4 | 64 participants (Actual) | Interventional | 2005-11-30 | Completed | ||
| Neuroprotective Effect of Dapsone in Patients With Aneurysmal Subarachnoid Hemorrhage: Prospective, Randomized, Double-Blinded, Placebo-Controlled, Clinical Trial[NCT05131295] | Phase 3 | 49 participants (Actual) | Interventional | 2007-09-05 | Completed | ||
| A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adoles[NCT00344006] | Phase 3 | 1,395 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Multi-centre, Randomised, Double-blind Study to Compare the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Chlorproguanil-dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults [NCT00371735] | Phase 3 | 900 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for dapsone and Anemia, Hemolytic, Acquired
| Article | Year |
|---|---|
G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications.
Topics: Anemia, Hemolytic; Animals; Antimalarials; Dapsone; Female; Glucosephosphate Dehydrogenase Deficienc | 2014 |
Dapsone-induced methemoglobinemia: a primer for clinicians.
Topics: Anemia, Hemolytic; Anti-Infective Agents; Dapsone; Enzyme Inhibitors; Humans; Methemoglobinemia; Met | 2011 |
Dapsone-induced hemolytic anemia.
Topics: Anemia, Hemolytic; Dapsone; Erythrocytes; Hemodynamics; Humans | 1995 |
Chemotherapy in Leprosy.
Topics: Acetamides; Anemia, Hemolytic; Aniline Compounds; Animals; Clofazimine; Dapsone; Disease Models, Ani | 1975 |
Adverse effects of dapsone.
Topics: Agranulocytosis; Anemia, Hemolytic; Dapsone; Erythrocytes; Humans; Leukocytes; Leukopenia; Methemogl | 1975 |
Chemoprophylaxis of malaria.
Topics: Adolescent; Adult; Africa; Anemia, Hemolytic; Asia; Australia; Child; Child, Preschool; Chloroquine; | 1986 |
2 trials available for dapsone and Anemia, Hemolytic, Acquired
| Article | Year |
|---|---|
Hematologic safety of dapsone gel, 5%, for topical treatment of acne vulgaris.
Topics: Acne Vulgaris; Adolescent; Adult; Anemia, Hemolytic; Child; Cross-Over Studies; Dapsone; Dermatologi | 2008 |
Glucose-6-phosphate dehydrogenase deficiency, chlorproguanil-dapsone with artesunate and post-treatment haemolysis in African children treated for uncomplicated malaria.
Topics: Africa South of the Sahara; Anemia, Hemolytic; Antimalarials; Artemisinins; Artesunate; Case-Control | 2012 |
74 other studies available for dapsone and Anemia, Hemolytic, Acquired
| Article | Year |
|---|---|
Bad luck comes in threes.
Topics: Anemia, Hemolytic; Dapsone; Humans; Methemoglobinemia; Pneumonia, Pneumocystis | 2023 |
Dapsone-induced Heinz-body haemolytic anaemia.
Topics: Anemia, Hemolytic; Dapsone; Humans | 2023 |
Hemolytic anemia associated with dapsone PCP prophylaxis in GBM patients with normal G6PD activity.
Topics: Anemia, Hemolytic; Dapsone; Humans | 2020 |
Dapsone Induced Agranulocytosis and Hemolytic Anemia in Immune Thrombocytopenic Purpura.
Topics: Agranulocytosis; Anemia, Hemolytic; Dapsone; Humans; Purpura; Purpura, Thrombocytopenic; Purpura, Th | 2020 |
Dapsone-Induced Hemolytic Anemia in Multiple Myeloma: Case Report of Various Differential Diagnoses.
Topics: Anemia, Hemolytic; Dapsone; Diagnosis, Differential; Female; Folic Acid Antagonists; Humans; Middle | 2020 |
Challenges in Managing a Lepromatous Leprosy Patient Complicated with Melioidosis Infection, Dapsone-Induced Methemoglobinemia, Hemolytic Anemia, and Lepra Reaction.
Topics: Adult; Anemia, Hemolytic; Dapsone; Drug Therapy, Combination; Female; Humans; Leprostatic Agents; Le | 2021 |
Dapsone safety in hematology patients: Pathways to optimizing Pneumocystis jirovecii pneumonia prophylaxis in hematology malignancy and transplant recipients.
Topics: Aged; Anemia, Hemolytic; Anti-Infective Agents; Antibiotic Prophylaxis; Dapsone; Female; Hematologic | 2018 |
Humanized mouse model of glucose 6-phosphate dehydrogenase deficiency for in vivo assessment of hemolytic toxicity.
Topics: Aminoquinolines; Anemia, Hemolytic; Animals; Antimalarials; Chloroquine; Combined Modality Therapy; | 2013 |
Hemolytic anemia in two patients with glioblastoma multiforme: A possible interaction between vorinostat and dapsone.
Topics: Anemia, Hemolytic; Dapsone; Female; Glioblastoma; Humans; Hydroxamic Acids; Middle Aged; Vorinostat | 2015 |
Incidence and patterns of hemolytic anemia in acute dapsone overdose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Dapsone; Drug Overdose; Humans; Incid | 2016 |
Full dapsone dose made possible by control of anaemia with darbepoetin-alpha.
Topics: Aged, 80 and over; Anemia, Hemolytic; Dapsone; Darbepoetin alfa; Dose-Response Relationship, Drug; E | 2008 |
Dapsone-induced hemolytic anemia in lung allograft recipients.
Topics: Anemia, Hemolytic; Anti-Infective Agents; Creatinine; Dapsone; Female; Hemoglobins; Humans; L-Lactat | 2008 |
Commentary to a paper by Flosadóttir & Bjarnason on full dapsone dose made possible by control of anaemia with darbepoetin-alpha.
Topics: Aged, 80 and over; Anemia, Hemolytic; Dapsone; Darbepoetin alfa; Dose-Response Relationship, Drug; E | 2008 |
Dapsone-induced haemolytic anaemia, hepatitis and agranulocytosis in a leprosy patient with normal glucose-6-phosphate-dehydrogenase activity.
Topics: Adult; Agranulocytosis; Anemia, Hemolytic; Chemical and Drug Induced Liver Injury; Dapsone; Glucosep | 2008 |
Dapsone hypersensitivity syndrome in non-leprosy patients: a retrospective study of its incidence in a tertiary referral center in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Hemolytic; Chemical and Drug Induced Liver Injur | 2009 |
The use of cimetidine to reduce dapsone-dependent haematological side-effects in a patient with mucous membrane pemphigoid.
Topics: Aged; Anemia, Hemolytic; Cimetidine; Dapsone; Humans; Immunosuppressive Agents; Male; Pemphigoid, Be | 2009 |
Agranulocytosis induced by multidrug therapy in leprosy treatment: a case report.
Topics: Adult; Agranulocytosis; Anemia, Hemolytic; Clofazimine; Dapsone; Drug Therapy, Combination; Female; | 2009 |
The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics.
Topics: Anemia, Hemolytic; Antimalarials; Dapsone; Drug Combinations; Drug Resistance; Glucosephosphate Dehy | 2010 |
Prevalence of G6PD deficiency in a large cohort of HIV-infected patients.
Topics: Adult; Aged; Anemia, Hemolytic; Anti-Infective Agents; Black or African American; Cohort Studies; Da | 2010 |
Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-HIV Agents; Anti-Infective Age | 2012 |
[Recurrent anemia in a 22-year-old woman].
Topics: Anemia, Hemolytic; Australia; Dapsone; Diagnosis, Differential; Female; Humans; Munchausen Syndrome; | 2012 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone.
Topics: Acute Disease; Adolescent; Africa; Anemia, Hemolytic; Antimalarials; Blood Transfusion; Child; Child | 2012 |
[Leprosy with an unusual course].
Topics: Anemia, Hemolytic; Child; Dapsone; Disease Progression; Drug Therapy, Combination; Erythema Nodosum; | 2012 |
[Rituximab (Mabthera) for treatment of rare autoimmune bullous skin disorders].
Topics: Adult; Anemia, Hemolytic; Anti-Infective Agents; Antibodies, Monoclonal, Murine-Derived; Biopsy; Dap | 2012 |
Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Brazil; Clofazimine; Dapsone; Drug Therapy, Combination; | 2012 |
[Dapsona syndrome].
Topics: Adult; Anemia, Hemolytic; Dapsone; Female; Folic Acid Antagonists; Humans; Stomatitis, Aphthous; Syn | 2002 |
Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus.
Topics: Adult; Anemia, Hemolytic; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathio | 2003 |
Heinz-body anaemia due to dapsone.
Topics: Anemia; Anemia, Hemolytic; Dapsone; Hemoglobinopathies; Humans; Sulfones | 1959 |
Hemolytic anemia induced by sulfoxone therapy, with investigations into the mechanisms of its production.
Topics: Anemia, Hemolytic; Dapsone; Humans; Sulfones | 1959 |
LABORATORY INVESTIGATIONS IN SULPHONE-INDUCED HAEMOLYTIC ANAEMIA.
Topics: Anemia; Anemia, Hemolytic; Bilirubin; Biomedical Research; Dapsone; Erythrocytes; Haptoglobins; Hein | 1964 |
Haemolytic anaemia during treatment of leprosy with diaminodiphenylsulphone by mouth.
Topics: Anemia; Anemia, Hemolytic; Dapsone; Humans; Leprosy; Mouth; Sulfones | 1951 |
Transfusion medicine illustrated: intravascular hemolysis with brown recluse spider envenomation.
Topics: Anemia, Hemolytic; Bilirubin; Child; Dapsone; Disseminated Intravascular Coagulation; Erythrocyte Tr | 2004 |
Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients.
Topics: Adult; Aged; Anemia, Hemolytic; Anti-Infective Agents; Antibiotic Prophylaxis; Dapsone; Female; Huma | 2005 |
Dapsone induced haemolytic anaemia in patients treated for ocular cicatricial pemphigoid.
Topics: Aged; Aged, 80 and over; Anemia, Hemolytic; Anti-Inflammatory Agents, Non-Steroidal; Dapsone; Eye Di | 2006 |
The sulfone syndrome secondary to dapsone prophylaxis in a patient undergoing unrelated hematopoietic stem cell transplantation.
Topics: Anemia, Hemolytic; Chemical and Drug Induced Liver Injury; Dapsone; Dermatitis, Exfoliative; Drug Hy | 2006 |
[Chronic atrophic polychondritis. Critical analysis of the therapeutic efficacy of dapsone. 2 cases].
Topics: Aged; Anemia, Hemolytic; Dapsone; Ear Cartilage; Ear Deformities, Acquired; Humans; Male; Middle Age | 1984 |
Dapsone hypersensitivity. The sulfone syndrome revisited.
Topics: Acne Vulgaris; Adolescent; Anemia, Hemolytic; Chemical and Drug Induced Liver Injury; Dapsone; Drug | 1981 |
[Role of dapsone in the treatment of Horton's disease and polymyalgia rheumatica].
Topics: Aged; Anemia, Hemolytic; Dapsone; Female; Follow-Up Studies; Giant Cell Arteritis; Humans; Iatrogeni | 1984 |
Hemolytic anemia induced by dapsone transmitted through breast milk.
Topics: Adult; Anemia, Hemolytic; Breast Feeding; Dapsone; Female; Humans; Infant | 1982 |
[Methemoglobinemia and hemolytic anemia induced by Disulon].
Topics: Acetylation; Anemia, Hemolytic; Dapsone; Humans; Methemoglobinemia; Phenotype; Time Factors | 1982 |
Is dapsone safe?
Topics: Anemia, Hemolytic; Dapsone; Glucosephosphate Dehydrogenase Deficiency; Humans; Leprosy | 1981 |
Dapsone haemolysis in leprosy. A preliminary report.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Bilirubin; Child; Dapsone; Female; Hemolysis; Humans; Le | 1981 |
Dapsone-induced haemolytic anaemia.
Topics: Anemia, Hemolytic; Dapsone; Humans | 1980 |
Permanent retinal damage following massive dapsone overdose.
Topics: Acute Kidney Injury; Adult; Anemia, Hemolytic; Dapsone; Fluorescein Angiography; Humans; Macula Lute | 1980 |
Dapsone-induced hemolytic anemia: effect of dapsone hydroxylamine on sulfhydryl status, membrane skeletal proteins and morphology of human and rat erythrocytes.
Topics: Anemia, Hemolytic; Animals; Dapsone; Erythrocytes; Humans; Male; Membrane Proteins; Microscopy, Elec | 1995 |
Dapsone-induced hemolytic anemia: role of glucose-6-phosphate dehydrogenase in the hemolytic response of rat erythrocytes to N-hydroxydapsone.
Topics: Amitrole; Androsterone; Anemia, Hemolytic; Animals; Dapsone; Erythrocytes; Glucosephosphate Dehydrog | 1995 |
Screening for glucose-6-phosphate dehydrogenase deficiency prior to dapsone therapy.
Topics: Adolescent; Anemia, Hemolytic; Contraindications; Dapsone; Female; Glucosephosphate Dehydrogenase De | 1994 |
Dapsone- and primaquine-induced methemoglobinemia in HIV-infected individuals.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-Infective Agents; Clindamycin; | 1996 |
Role of lipid peroxidation in dapsone-induced hemolytic anemia.
Topics: Anemia, Hemolytic; Animals; Dapsone; Erythrocyte Membrane; Erythrocytes; Fatty Acids, Unsaturated; F | 1998 |
Studies on dapsone induced haemolytic anaemia. I. Methaemoglobin production and G-6-PD activity in correlation with dapsone dosage.
Topics: Anemia, Hemolytic; Dapsone; Dose-Response Relationship, Drug; Glucosephosphate Dehydrogenase; Humans | 1979 |
Dapsone-induced jaundice.
Topics: Adolescent; Adult; Anemia, Hemolytic; Cholestasis; Dapsone; Female; Humans; Jaundice; Male | 1978 |
High dose dapsone toxicity.
Topics: Aged; Anemia, Hemolytic; Dapsone; Dermatitis Herpetiformis; Female; Foot Diseases; Gangrene; Humans; | 1976 |
Proceedings: "Asymptomatic" treated dermatitis herpetiformis - a misnomer.
Topics: Anemia, Hemolytic; Dapsone; Dermatitis Herpetiformis; Female; Humans; Male; Terminology as Topic | 1975 |
Serum hemopexin in patients with dermatitis herpetiformis on dapsone (di(4-aminophenyl)sulphone).
Topics: Adult; Aged; Anemia, Hemolytic; Dapsone; Dermatitis Herpetiformis; Erythrocyte Count; Female; Haptog | 1975 |
Dapsone-induced hemolytic anemia: effect of N-hydroxy dapsone on the sulfhydryl status and membrane proteins of rat erythrocytes.
Topics: Anemia, Hemolytic; Animals; Dapsone; Dithiothreitol; Erythrocyte Membrane; Erythrocytes; Glutathione | 1992 |
Dapsone-induced methemoglobinemia and hemolytic anemia.
Topics: Adult; Anemia, Hemolytic; Charcoal; Dapsone; Drug Monitoring; Female; Hemoperfusion; Humans; Methemo | 1992 |
Peripheral neuropathy and haemolytic anaemia with cherry red spot on macula in dapsone poisoning.
Topics: Adolescent; Anemia, Hemolytic; Dapsone; Female; Humans; Leprosy, Tuberculoid; Macula Lutea; Peripher | 1990 |
Gall-bladder perforation after long-term dapsone therapy.
Topics: Abdomen, Acute; Aged; Anemia, Hemolytic; Cholecystitis; Dapsone; Dermatitis Herpetiformis; Humans; M | 1990 |
Dapsone-induced haemolytic anaemia and agranulocytosis in a patient with normal glucose-6-phosphate-dehydrogenase activity.
Topics: Aged; Agranulocytosis; Anemia, Hemolytic; Dapsone; Female; Glucosephosphate Dehydrogenase; Humans | 1989 |
Stimulation of K-C1 cotransport in rat red cells by a hemolytic anemia-producing metabolite of dapsone.
Topics: 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid; 4,4'-Diisothiocyanostilbene-2,2'-Disulfo | 1989 |
Acne fulminans with dapsone induced haemolysis: a case report.
Topics: Acne Vulgaris; Adult; Anemia, Hemolytic; Dapsone; Female; Humans | 1987 |
Case report: dapsone hypersensitivity syndrome associated with treatment of the bite of a brown recluse spider.
Topics: Anemia, Hemolytic; Dapsone; Drug Hypersensitivity; Fever; Headache; Hepatitis; Humans; Male; Middle | 1988 |
Role of dapsone hydroxylamine in dapsone-induced hemolytic anemia.
Topics: Anemia, Hemolytic; Animals; Biotransformation; Chromium; Dapsone; Hydroxylamines; Male; Rats; Rats, | 1988 |
Dapsone-associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait.
Topics: 2,3-Diphosphoglycerate; Adult; Anemia, Hemolytic; Cambodia; Dapsone; Diphosphoglyceric Acids; Female | 1987 |
Antileprosy drugs.
Topics: Anemia, Hemolytic; Aniline Compounds; Anti-Bacterial Agents; Dapsone; Drug Resistance, Microbial; Hu | 1971 |
Exacerbation of dapsone-induced Heinz body hemolytic anemia following treatment with methylene blue.
Topics: Anemia, Hemolytic; Dapsone; Erythrocytes; Female; Glutathione; Heinz Bodies; Humans; Lupus Erythemat | 1974 |
A case of acute side-reactions to diaminodiphenylsulphone (DDS).
Topics: Adolescent; Anemia, Hemolytic; Cyanosis; Dapsone; Exchange Transfusion, Whole Blood; Female; Humans; | 1968 |
[Ulcer on white atrophy: hemolytic anemia caused by disulone revealing an erythrocytic glutathione reductase deficiency].
Topics: Anemia, Hemolytic; Atrophy; Dapsone; Erythrocytes; Erythrocytes, Abnormal; Female; Glutathione Reduc | 1972 |
Haemolytic effects of DDS in leprosy patients.
Topics: Adult; Anemia, Hemolytic; Dapsone; Erythrocytes; Female; Glucosephosphate Dehydrogenase Deficiency; | 1972 |
Glucose-6-phosphate dehydrogenase deficiency and intravascular haemolysis.
Topics: Adolescent; Adult; Anemia, Hemolytic; Aspirin; Dapsone; Female; Glucosephosphate Dehydrogenase Defic | 1974 |
Neonatal haemolytic disease due to dapsone.
Topics: Anemia, Hemolytic; Anemia, Neonatal; Dapsone; Female; Glucosephosphate Dehydrogenase; Humans; Infant | 1968 |
Supplemental sulfone (dapsone) therapy. Use in treatment of chloroquine-resistant falciparum malaria.
Topics: Adolescent; Adult; Anemia, Hemolytic; Chemical Phenomena; Chemistry, Physical; Dapsone; Humans; Mala | 1967 |
Anaemia in dermatitis herpetiformis. The role of dapsone-induced haemolysis and malabsorption.
Topics: Adult; Aged; Anemia, Hemolytic; Anemia, Hypochromic; Anemia, Pernicious; Dapsone; Dermatitis Herpeti | 1970 |
[Hematological changes in acute accidental poisoning with sulfones].
Topics: Anemia, Hemolytic; Blood; Child; Child, Preschool; Dapsone; Female; Glucosephosphate Dehydrogenase; | 1966 |